Fezakinumab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | IL13 |
Clinical data | |
Legal status | ? |
Identifiers | |
CAS number | 1007106-86-6 |
ATC code | None |
UNII | 0S77U25XZ3 |
Chemical data | |
Formula | C6408H9873N1706O2016S44 |
Mol. mass | 143.87 kDa |
(what is this?) (verify) | |
Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, [3] but data was not released. Development was discontinued in August 2011.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab". American Medical Association.
- ↑ page 6; http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf
- ↑ http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.